Table 2 The expression of FLT3 and its clinical relevance.
Characteristics | Relative expression levels of FLT3 | P value | |
|---|---|---|---|
High (n = 149) | Low (n = 148) | ||
Age, mean ± sd | 51.013 ± 10.705 | 52.142 ± 9.9878 | 0.348 |
Gender, n (%) | 0.052 | ||
Male | 116 (39.1%) | 128 (43.1%) | |
Female | 33 (11.1%) | 20 (6.7%) | |
Liver cirrhosis, n (%) | < 0.001 | ||
Yes | 128 (43.1%) | 91 (30.6%) | |
No | 21 (7.1%) | 57 (19.2%) | |
AFP, n (%) | 0.594 | ||
Normal | 48 (16.2%) | 52 (17.5%) | |
Increased | 101 (34%) | 96 (32.3%) | |
ALT, n (%) | 0.129 | ||
Normal | 12 (4%) | 20 (6.7%) | |
Increased | 137 (46.1%) | 128 (43.1%) | |
Tumor size, n (%) | 0.176 | ||
≤ 5 cm | 125 (42.1%) | 115 (38.7%) | |
>5 cm | 24 (8.1%) | 33 (11.1%) | |
Tumor Number, n (%) | 0.767 | ||
Single | 143 (48.1%) | 141 (47.5%) | |
Multiple | 6 (2%) | 7 (2.4%) | |
Tumor differentiation, n (%) | 0.760 | ||
I + II | 115 (38.7%) | 112 (37.7%) | |
III + IV | 34 (11.4%) | 36 (12.1%) | |
T stage, n (%) | 0.067 | ||
T1 + T2 | 99 (33.3%) | 83 (27.9%) | |
T3 + T4 | 50 (16.8%) | 65 (21.9%) | |
BCLC, n (%) | 0.100 | ||
A | 48 (16.2%) | 48 (16.2%) | |
B | 101 (34%) | 113 (38%) | |
